Brachytherapy‐related dysuria
OBJECTIVE To evaluate the incidence and temporal resolution of dysuria after permanent prostate brachytherapy, and to identify predictors of brachytherapy‐related dysuria. PATIENTS AND METHODS The study included 130 patients with no history of transurethral resection of the prostate before treatment...
Saved in:
Published in | BJU international Vol. 95; no. 4; pp. 597 - 602 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Science Ltd
01.03.2005
Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | OBJECTIVE
To evaluate the incidence and temporal resolution of dysuria after permanent prostate brachytherapy, and to identify predictors of brachytherapy‐related dysuria.
PATIENTS AND METHODS
The study included 130 patients with no history of transurethral resection of the prostate before treatment, who had brachytherapy on one of two prospective randomized trials, with explicitly planned and executed urethral‐sparing techniques (100–150% minimum peripheral dose) using either 103Pd or 125I for clinical T1c–T2c prostate cancer. The median follow‐up was 22.6 months. An α‐blocker was initiated either prophylactically 2 weeks before implantation and continued at least until the International Prostate Symptom Score (IPSS) returned to normal, or withheld until the onset of significant brachytherapy‐related urinary morbidity. Dysuria was evaluated on a 0–10 scale, before brachytherapy and then at 1, 3, 6 and 12 months afterward, with a median of four dysuria questionnaires per patient. Clinical, treatment and dosimetric variables evaluated included α‐blocker, age, IPSS before and the maximum after treatment, prostate volume on ultrasonography, hormonal status, supplemental radiotherapy, isotope, urethral dose, V100/200, D90, and time to obtaining a normal IPSS.
RESULTS
The maximum incidence of dysuria was 85% at 1 month after brachytherapy, with subsequent resolution over time. The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months. Patients with dysuria had a statistically higher IPSS. The dysuria resolved faster in patients implanted with 103Pd but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy. In multivariate analysis, prophylactic α‐blockers resulted in statistically lower maximum dysuria scores, while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
CONCLUSIONS
Dysuria is common after brachytherapy but is typically mild. Prophylactic α‐blockers gave significantly lower maximum dysuria scores but did not affect the time to the resolution of dysuria. The maximum IPSS after the implant was the best predictor of the resolution of dysuria. |
---|---|
AbstractList | To evaluate the incidence and temporal resolution of dysuria after permanent prostate brachytherapy, and to identify predictors of brachytherapy-related dysuria.
The study included 130 patients with no history of transurethral resection of the prostate before treatment, who had brachytherapy on one of two prospective randomized trials, with explicitly planned and executed urethral-sparing techniques (100-150% minimum peripheral dose) using either 103Pd or 125I for clinical T1c-T2c prostate cancer. The median follow-up was 22.6 months. An alpha-blocker was initiated either prophylactically 2 weeks before implantation and continued at least until the International Prostate Symptom Score (IPSS) returned to normal, or withheld until the onset of significant brachytherapy-related urinary morbidity. Dysuria was evaluated on a 0-10 scale, before brachytherapy and then at 1, 3, 6 and 12 months afterward, with a median of four dysuria questionnaires per patient. Clinical, treatment and dosimetric variables evaluated included alpha-blocker, age, IPSS before and the maximum after treatment, prostate volume on ultrasonography, hormonal status, supplemental radiotherapy, isotope, urethral dose, V(100/200), D90, and time to obtaining a normal IPSS.
The maximum incidence of dysuria was 85% at 1 month after brachytherapy, with subsequent resolution over time. The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months. Patients with dysuria had a statistically higher IPSS. The dysuria resolved faster in patients implanted with 103Pd but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy. In multivariate analysis, prophylactic alpha-blockers resulted in statistically lower maximum dysuria scores, while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria.
Dysuria is common after brachytherapy but is typically mild. Prophylactic alpha-blockers gave significantly lower maximum dysuria scores but did not affect the time to the resolution of dysuria. The maximum IPSS after the implant was the best predictor of the resolution of dysuria. OBJECTIVE To evaluate the incidence and temporal resolution of dysuria after permanent prostate brachytherapy, and to identify predictors of brachytherapy‐related dysuria. PATIENTS AND METHODS The study included 130 patients with no history of transurethral resection of the prostate before treatment, who had brachytherapy on one of two prospective randomized trials, with explicitly planned and executed urethral‐sparing techniques (100–150% minimum peripheral dose) using either 103 Pd or 125 I for clinical T1c–T2c prostate cancer. The median follow‐up was 22.6 months. An α‐blocker was initiated either prophylactically 2 weeks before implantation and continued at least until the International Prostate Symptom Score (IPSS) returned to normal, or withheld until the onset of significant brachytherapy‐related urinary morbidity. Dysuria was evaluated on a 0–10 scale, before brachytherapy and then at 1, 3, 6 and 12 months afterward, with a median of four dysuria questionnaires per patient. Clinical, treatment and dosimetric variables evaluated included α‐blocker, age, IPSS before and the maximum after treatment, prostate volume on ultrasonography, hormonal status, supplemental radiotherapy, isotope, urethral dose, V 100/200 , D 90 , and time to obtaining a normal IPSS. RESULTS The maximum incidence of dysuria was 85% at 1 month after brachytherapy, with subsequent resolution over time. The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months. Patients with dysuria had a statistically higher IPSS. The dysuria resolved faster in patients implanted with 103 Pd but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy. In multivariate analysis, prophylactic α‐blockers resulted in statistically lower maximum dysuria scores, while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria. CONCLUSIONS Dysuria is common after brachytherapy but is typically mild. Prophylactic α‐blockers gave significantly lower maximum dysuria scores but did not affect the time to the resolution of dysuria. The maximum IPSS after the implant was the best predictor of the resolution of dysuria. OBJECTIVE To evaluate the incidence and temporal resolution of dysuria after permanent prostate brachytherapy, and to identify predictors of brachytherapy‐related dysuria. PATIENTS AND METHODS The study included 130 patients with no history of transurethral resection of the prostate before treatment, who had brachytherapy on one of two prospective randomized trials, with explicitly planned and executed urethral‐sparing techniques (100–150% minimum peripheral dose) using either 103Pd or 125I for clinical T1c–T2c prostate cancer. The median follow‐up was 22.6 months. An α‐blocker was initiated either prophylactically 2 weeks before implantation and continued at least until the International Prostate Symptom Score (IPSS) returned to normal, or withheld until the onset of significant brachytherapy‐related urinary morbidity. Dysuria was evaluated on a 0–10 scale, before brachytherapy and then at 1, 3, 6 and 12 months afterward, with a median of four dysuria questionnaires per patient. Clinical, treatment and dosimetric variables evaluated included α‐blocker, age, IPSS before and the maximum after treatment, prostate volume on ultrasonography, hormonal status, supplemental radiotherapy, isotope, urethral dose, V100/200, D90, and time to obtaining a normal IPSS. RESULTS The maximum incidence of dysuria was 85% at 1 month after brachytherapy, with subsequent resolution over time. The use of prophylactic tamsulosin resulted in a statistically lower dysuria severity score (difference of 2.7 vs 4.2, P < 0.005) at 1 month, with no discernible differences at 3, 6, 12 and 18 months. Patients with dysuria had a statistically higher IPSS. The dysuria resolved faster in patients implanted with 103Pd but was unaffected by the use of supplemental radiotherapy and/or androgen deprivation therapy. In multivariate analysis, prophylactic α‐blockers resulted in statistically lower maximum dysuria scores, while the maximum IPSS after implantation and isotope type (but only at 6 months) were the best predictors of the resolution of dysuria. CONCLUSIONS Dysuria is common after brachytherapy but is typically mild. Prophylactic α‐blockers gave significantly lower maximum dysuria scores but did not affect the time to the resolution of dysuria. The maximum IPSS after the implant was the best predictor of the resolution of dysuria. |
Author | Galbreath, Robert W. Allen, Zachariah Merrick, Gregory S. Butler, Wayne M. Wallner, Kent E. Lief, Jonathan H. |
Author_xml | – sequence: 1 givenname: Gregory S. surname: Merrick fullname: Merrick, Gregory S. – sequence: 2 givenname: Wayne M. surname: Butler fullname: Butler, Wayne M. – sequence: 3 givenname: Kent E. surname: Wallner fullname: Wallner, Kent E. – sequence: 4 givenname: Zachariah surname: Allen fullname: Allen, Zachariah – sequence: 5 givenname: Robert W. surname: Galbreath fullname: Galbreath, Robert W. – sequence: 6 givenname: Jonathan H. surname: Lief fullname: Lief, Jonathan H. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16515659$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15705087$$D View this record in MEDLINE/PubMed |
BookMark | eNqNj0tOwzAQhi1URFvgCtANy4RxHE-SBQta8VQlNlRiZzn2RE2VPmS3otlxBM7ISUhooVu8GI_G3z_y12edxXJBjA04hLw517OQxxgHMYe3MAKQIUgRY7g9Yr2_h85vDxl2Wd_7GUAzQHnCulwmICFNeuxy6LSZ1uspOb2qvz4-HVV6TXZga79xpT5jx4WuPJ3v71M2ub97HT0G45eHp9HtODAxCgwsGUzSPIFcW5IZRlxQkedgitSgTHVmikRb1HGExkQcuRC2qSAoyiLKUnHK0t1e45beOyrUypVz7WrFQbXOaqZaHdWqqdZZ_TirbRO92EVXm3xO9hDcSzbA1R7Q3uiqcHphSn_gUHKJMmu4mx33XlZU__sDavg8aTvxDWw-dFk |
CitedBy_id | crossref_primary_10_1016_j_canrad_2009_08_144 crossref_primary_10_1007_s00345_014_1239_z crossref_primary_10_1155_2014_140654 crossref_primary_10_1157_13076940 crossref_primary_10_1097_PPO_0b013e31818f5aa7 crossref_primary_10_1002_14651858_CD008871_pub2 crossref_primary_10_1016_j_ctim_2014_11_004 crossref_primary_10_1016_j_ijrobp_2011_04_026 crossref_primary_10_1186_1477_7525_5_38 crossref_primary_10_1111_j_1442_2042_2012_03105_x crossref_primary_10_1016_S0210_4806_08_73892_0 crossref_primary_10_1097_COC_0b013e31819cd364 crossref_primary_10_1007_s11934_006_0022_0 crossref_primary_10_1089_cbr_2009_0648 crossref_primary_10_1007_s11884_007_0017_9 crossref_primary_10_1016_j_radonc_2006_11_006 crossref_primary_10_1007_s00432_017_2367_9 crossref_primary_10_1007_s11918_006_0017_9 crossref_primary_10_1111_j_1464_410X_2009_09096_x |
Cites_doi | 10.1016/S0022-5347(01)62542-4 10.1097/00130404-200201000-00012 10.1016/S0360-3016(99)00176-5 10.1016/S0360-3016(01)01530-9 10.1016/S0090-4295(95)96950-0 10.1016/S0360-3016(00)01380-8 10.1016/S0090-4295(02)02247-1 10.1016/0360-3016(94)00599-G 10.1016/0360-3016(93)90013-L 10.1016/S0360-3016(99)00405-8 10.1016/S0360-3016(03)01051-4 10.1118/1.597458 10.1097/01.ju.0000117811.40279.19 10.1016/0360-3016(94)90119-8 10.1016/S0360-3016(02)04279-7 10.1016/S0360-3016(99)00525-8 10.1016/0360-3016(95)00060-C 10.1016/S0090-4295(02)01840-X 10.1016/S0360-3016(02)04527-3 10.1016/S0360-3016(02)04600-X 10.1016/0360-3016(91)90732-J |
ContentType | Journal Article |
Copyright | 2005 INIST-CNRS |
Copyright_xml | – notice: 2005 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1111/j.1464-410X.2005.05346.x |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1464-410X |
EndPage | 602 |
ExternalDocumentID | 10_1111_j_1464_410X_2005_05346_x 15705087 16515659 BJU5346 |
Genre | article Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT 08R 1OB AAPBV AAUGY AAVGM ABHUG ABPTK ABWRO ACXME ADAWD ADDAD AFVGU AGJLS IQODW ZA5 CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c4636-dec678b70bade596213efbb0cf8c658a9cf7ad6a426cc216133d16103e292e983 |
IEDL.DBID | DR2 |
ISSN | 1464-4096 |
IngestDate | Fri Aug 23 01:07:50 EDT 2024 Sat Sep 28 07:52:27 EDT 2024 Sun Oct 22 16:09:41 EDT 2023 Sat Aug 24 00:55:23 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Human urinary morbidity Nephrology Urinary system disease Prostate disease Malignant tumor Radiotherapy Prostate adenocarcinoma Urology Quality of life Voiding dysfunction Treatment Radiation injury Complication prostate brachytherapy Male genital diseases Prostate cancer Curietherapy Dysuria |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4636-dec678b70bade596213efbb0cf8c658a9cf7ad6a426cc216133d16103e292e983 |
PMID | 15705087 |
PageCount | 6 |
ParticipantIDs | crossref_primary_10_1111_j_1464_410X_2005_05346_x pubmed_primary_15705087 pascalfrancis_primary_16515659 wiley_primary_10_1111_j_1464_410X_2005_05346_x_BJU5346 |
PublicationCentury | 2000 |
PublicationDate | March 2005 |
PublicationDateYYYYMMDD | 2005-03-01 |
PublicationDate_xml | – month: 03 year: 2005 text: March 2005 |
PublicationDecade | 2000 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
PublicationTitle | BJU international |
PublicationTitleAlternate | BJU Int |
PublicationYear | 2005 |
Publisher | Blackwell Science Ltd Blackwell |
Publisher_xml | – name: Blackwell Science Ltd – name: Blackwell |
References | 1995; 31 1993; 25 1998; 160 2001; 50 2000; 47 2000; 6 2000; 48 1991; 21 2000; 46 1995; 45 1995; 22 2004; 171 2002; 8 1995; 32 2003; 57 1999; 45 1997 2002; 60 1994; 28 2003; 61 2003; 55 1998; 14 2003; 56 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 e_1_2_7_9_2 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 e_1_2_7_16_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_25_2 e_1_2_7_24_2 e_1_2_7_12_2 e_1_2_7_23_2 e_1_2_7_11_2 e_1_2_7_22_2 e_1_2_7_10_2 e_1_2_7_21_2 e_1_2_7_20_2 Mears EM Jr (e_1_2_7_13_2) 1997 Merrick GS (e_1_2_7_17_2) 2000; 6 Merrick GS (e_1_2_7_18_2) 1998; 14 |
References_xml | – volume: 45 start-page: 56 year: 1999 end-page: 67 article-title: Urinary morbidity following ultrasound‐guided transperineal prostate seed implantation publication-title: Int J Radiat Oncol Biol Phys – volume: 48 start-page: 1575 year: 2000 end-page: 82 article-title: Comparison of dose length, area, and Volume histograms as quantifiers of urethral dose in prostate brachytherapy publication-title: Int J Radiat Oncol Biol Phys – volume: 6 start-page: 78 year: 2000 end-page: 84 article-title: Modified uniform seed loading for prostate brachytherapy. Rationale, design and evaluation publication-title: Tech Urol – volume: 31 start-page: 1341 year: 1995 end-page: 6 article-title: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Research and Treatment of Cancer (EORTC) publication-title: Int J Radiat Oncol Biol Phys – volume: 47 start-page: 121 year: 2000 end-page: 5 article-title: Temporal resolution of urinary morbidity following prostate brachytherapy publication-title: Int J Radiat Oncol Biol Phys – start-page: 624 year: 1997 end-page: 6 – volume: 45 start-page: 87 year: 1995 end-page: 92 article-title: Transperineal palladium 103 prostate brachytherapy. Analysis of morbidity and seed migration publication-title: Urology – volume: 160 start-page: 1379 year: 1998 end-page: 82 article-title: Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate publication-title: J Urol – volume: 14 start-page: 113 year: 1998 end-page: 21 article-title: The impact of Gleason score as a criterion for prostate brachytherapy patient selection publication-title: J Brachyther Int – volume: 56 start-page: 454 year: 2003 end-page: 61 article-title: Long‐term urinary quality of life following permanent prostate brachytherapy publication-title: Int J Radiat Oncol Biol Phys – volume: 22 start-page: 209 year: 1995 end-page: 34 article-title: Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group, 43 publication-title: Med Phys – volume: 55 start-page: 979 year: 2003 end-page: 85 article-title: Dysuria after permanent prostate brachytherapy publication-title: Int J Radiat Oncol Biol Phys – volume: 32 start-page: 465 year: 1995 end-page: 71 article-title: Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I‐125 prostate brachytherapy publication-title: Int J Radiat Oncol Biol Phys – volume: 60 start-page: 650 year: 2002 end-page: 5 article-title: Prophylactic versus therapeutic alpha blockers following permanent prostate brachytherapy publication-title: Urology – volume: 171 start-page: 1594 year: 2004 end-page: 7 article-title: Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial publication-title: J Urol – volume: 55 start-page: 1288 year: 2003 end-page: 93 article-title: The effect of supplemental beam radiation on prostate brachytherapy‐related morbidity: Morbidity outcomes from two prospective randomized multicenter trials publication-title: Int J Radiat Oncol Biol Phys – volume: 21 start-page: 935 year: 1991 end-page: 9 article-title: Long‐term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: An analysis of RTOG studies 7506 and 7706 publication-title: Int J Radiat Oncol Biol Phys – volume: 50 start-page: 937 year: 2001 end-page: 45 article-title: Acute urinary toxicity following transperineal prostate brachytherapy using a modified quimby loading approach publication-title: Int J Radiat Oncol Biol Phys – volume: 8 start-page: 67 year: 2002 end-page: 73 article-title: I‐125 versus Pd‐103 for low‐risk prostate cancer: Morbidity outcomes from a prospective randomized multicenter trial publication-title: Cancer J – volume: 46 start-page: 215 year: 2000 end-page: 20 article-title: Seed fixity in the prostate/periprostatic region following brachytherapy publication-title: Int J Radiat Oncol Biol Phys – volume: 61 start-page: 408 year: 2003 end-page: 11 article-title: Gross hematuria after prostate brachytherapy publication-title: Urology – volume: 25 start-page: 661 year: 1993 end-page: 7 article-title: Short‐term morbidity from CT‐planned transperineal I‐125 prostate implants publication-title: Int J Radiat Oncol Biol Phys – volume: 28 start-page: 985 year: 1994 end-page: 90 article-title: Treatment‐related symptoms during the first year following transperineal I prostate implantation publication-title: Int J Radiat Oncol Biol Phys – volume: 57 start-page: S229 year: 2003 article-title: The role of prophylactic tamsulosin (Flomax) in patients undergoing prostate 125‐I seed implants for prostate carcinoma: Final report of double‐blind placebo‐controlled randomized study publication-title: Int J Radiat Oncol Biol Phys – ident: e_1_2_7_3_2 doi: 10.1016/S0022-5347(01)62542-4 – ident: e_1_2_7_15_2 doi: 10.1097/00130404-200201000-00012 – ident: e_1_2_7_4_2 doi: 10.1016/S0360-3016(99)00176-5 – ident: e_1_2_7_5_2 doi: 10.1016/S0360-3016(01)01530-9 – ident: e_1_2_7_9_2 doi: 10.1016/S0090-4295(95)96950-0 – ident: e_1_2_7_21_2 doi: 10.1016/S0360-3016(00)01380-8 – ident: e_1_2_7_23_2 doi: 10.1016/S0090-4295(02)02247-1 – ident: e_1_2_7_25_2 doi: 10.1016/0360-3016(94)00599-G – ident: e_1_2_7_7_2 doi: 10.1016/0360-3016(93)90013-L – ident: e_1_2_7_20_2 doi: 10.1016/S0360-3016(99)00405-8 – ident: e_1_2_7_24_2 doi: 10.1016/S0360-3016(03)01051-4 – volume: 6 start-page: 78 year: 2000 ident: e_1_2_7_17_2 article-title: Modified uniform seed loading for prostate brachytherapy. Rationale, design and evaluation publication-title: Tech Urol contributor: fullname: Merrick GS – ident: e_1_2_7_19_2 doi: 10.1118/1.597458 – ident: e_1_2_7_14_2 doi: 10.1097/01.ju.0000117811.40279.19 – ident: e_1_2_7_8_2 doi: 10.1016/0360-3016(94)90119-8 – start-page: 624 volume-title: Campbell's Urology. year: 1997 ident: e_1_2_7_13_2 contributor: fullname: Mears EM Jr – ident: e_1_2_7_6_2 doi: 10.1016/S0360-3016(02)04279-7 – ident: e_1_2_7_2_2 doi: 10.1016/S0360-3016(99)00525-8 – ident: e_1_2_7_10_2 doi: 10.1016/0360-3016(95)00060-C – volume: 14 start-page: 113 year: 1998 ident: e_1_2_7_18_2 article-title: The impact of Gleason score as a criterion for prostate brachytherapy patient selection publication-title: J Brachyther Int contributor: fullname: Merrick GS – ident: e_1_2_7_12_2 doi: 10.1016/S0090-4295(02)01840-X – ident: e_1_2_7_16_2 doi: 10.1016/S0360-3016(02)04527-3 – ident: e_1_2_7_22_2 doi: 10.1016/S0360-3016(02)04600-X – ident: e_1_2_7_11_2 doi: 10.1016/0360-3016(91)90732-J |
SSID | ssj0014665 |
Score | 1.9153246 |
Snippet | OBJECTIVE
To evaluate the incidence and temporal resolution of dysuria after permanent prostate brachytherapy, and to identify predictors of... To evaluate the incidence and temporal resolution of dysuria after permanent prostate brachytherapy, and to identify predictors of brachytherapy-related... |
SourceID | crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 597 |
SubjectTerms | Adrenergic alpha-Antagonists - therapeutic use Aged Antineoplastic Agents - therapeutic use Biological and medical sciences brachytherapy Brachytherapy - adverse effects dysuria Follow-Up Studies Genital system. Mammary gland Humans Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Prospective Studies prostate Prostatic Neoplasms - radiotherapy Quality of Life Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Severity of Illness Index Sulfonamides - therapeutic use Treatment Outcome urinary morbidity Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland Urination Disorders - drug therapy Urination Disorders - etiology |
Title | Brachytherapy‐related dysuria |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2005.05346.x https://www.ncbi.nlm.nih.gov/pubmed/15705087 |
Volume | 95 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEB6kBxHE9yM-ag9eU9LdZJMcrVhKoR7EQm9hX0Eo1NIHWE_-BH-jv8TZ3fSR4kHEWyCZhHls5stm5huAW41JNWGK-TSisR_mxDQrx9JXiC4IQmAaaNON3H1k7V7Y6Uf9ov7J9MI4fojlhptZGfZ9bRY4F5PNRR76YSPoF1sjEQ1Z3eBJw6tn8NHTkkkKL7VTJZ0IwvZyUc-PNyplqt0Rn6DRcjftYi1drUNam5Na-zBYaONKUQb12VTU5fsG0eP_qHsAewV0rd25WDuELT08gu1u8XP-GG6aYy5f5q6ja_718Wn7ZLSqqflkhnF-Ar3Ww_N92y_mL_jS0Ij5SktMZSIOBFfaTOlpUJ0LEcg8kQhceCrzmCvGMclLSdC5lBoXB1STlOg0oadQGb4O9TnUME54SoRklrA_pYKInOkkTASjCiPEg8bC1tnI0Wxkpc-TMDOam6GZUWY1z948qJacshI0491ZlHpw5ry0OhPFASLS2ANmbf3rZ2XNTs8cXfxV8BJ2LOmrrV67gsp0PNPXCGemomoD9RtyEuSv |
link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEB6kggri-xEfbQ9eU9JsskmOVi21tj1IC72F7CMISi19gPXkT_A3-kuc3U2feBDxFkg2YXZmMl82O98HcCWxqIZUUJv4JLC91FXNygG3BaILFyEwcaTqRm62aK3j1bt-N5MDUr0whh9ituCmMkO_r1WCqwXp1Sz3bK_sdLO1EZ94tISAch2z31dZevs445LCa7WupBmDwH15W8-Pd1qqVdv9ZIjTlhq9i4WCtQhqdVWq7sLL1B6zGeW5NB6xEn9foXr8J4P3YCdDr8VrE277sCZ7B7DRzP7PH0KhMkj408Q0dU2-Pj51q4wURTEZjjHUj6BTvWvf1OxMgsHmiknMFpJjNWOBwxIhlVBPmciUMYenIUfskkQ8DRJBE6zznLvoX0KUlx0i3ciVUUiOIdd77clTKGKoJJHLONWc_RFhLkupDL2QUSIwSCwoTyc77humjXjpC8WLleVKN9OPteXxmwX5Ja_MByqFd-pHFpwYN83P-IGDoDSwgOrJ_vWz4kq9o47O_jqwAJu1drMRN-5bD-ewpTlg9Wa2C8iNBmN5iehmxPI6ar8B6Yzozw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ZS8NAEB6kQhHE-6hH2wdfU9LdzSZ5tNZSqy0iFvoWskcQCrX0AOuTP8Hf6C9xj_RI8UHEt0AyCbMzm_l2d-YbgCupgmpABXWwh32HJEgXK_vcEQpdIAWBsSt1NXK7Q5td0up5vTT_SdfCWH6IxYabnhnmf60n-FAk65OcOKTq9tKtEQ8TWlF4cpNQjPRCrP60oJJSz5q2klZG4fZsVs-Pb8qEqu1hPFajlth2FyvxahXTmqDU2IX-XB2bi9KvTCeswt_XmB7_R9892Emxa_naOts-bMjBAeTb6en8IZRqo5i_zGxJ1-zr49MUykhRFrPxVDn6EXQbt883TSdtwOBwzSPmCMlVLGO-y2IhdZueKpYJYy5PAq6QSxzyxI8FjVWU5xwp62KsbexiiUIkwwAfQ27wOpCnUFaOEoeIcWoY-0PMEEuoDEjAKBbKRQpQnY91NLQ8G1FmfUIirbnumulFRvPorQDFjFGWgrq_O_XCApxYKy3veL6rIKlfAGrG-tffimqtrr46-6tgCfKP9Ub0cNe5P4ctQwBrMtkuIDcZTeWlgjYTVjQ--w0yBud- |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brachytherapy-related+dysuria&rft.jtitle=BJU+international&rft.au=MERRICK%2C+Gregory+S&rft.au=BUTLER%2C+Wayne+M&rft.au=WALLNER%2C+Kent+E&rft.au=ALLEN%2C+Zachariah&rft.date=2005-03-01&rft.pub=Blackwell&rft.issn=1464-4096&rft.eissn=1464-410X&rft.volume=95&rft.issue=4&rft.spage=597&rft.epage=602&rft_id=info:doi/10.1111%2Fj.1464-410X.2005.05346.x&rft.externalDBID=n%2Fa&rft.externalDocID=16515659 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |